Welcome to our dedicated page for PROCEPT BioRobotics SEC filings (Ticker: PRCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PROCEPT BioRobotics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PROCEPT BioRobotics's regulatory disclosures and financial reporting.
PROCEPT BioRobotics director Thomas M. Prescott received new equity awards in the form of restricted stock units and stock options. He was granted 3,315 restricted stock units, each representing a right to receive one share of Common Stock, and now holds 7,211 shares of Common Stock following the award. The RSUs vest in full on the earlier of the one-year anniversary of the June 9, 2026 grant date or the next annual meeting, subject to continued service.
He was also granted stock options for 5,853 shares of Common Stock at an exercise price of $28.78 per share, vesting on the same schedule and expiring on June 8, 2036. These are compensation-related grants rather than open‑market purchases or sales.
PROCEPT BioRobotics director Dan Puckett received new equity awards. He was granted 3,315 restricted stock units, each representing a right to one share of common stock, increasing his direct common stock holdings to 8,791 shares after the grant.
He was also granted stock options for 5,853 shares of common stock at an exercise price of $28.78 per share, expiring on June 8, 2036. Both the RSUs and options vest in full on the earlier of one year from the June 9, 2026 grant date or the next annual meeting, subject to continued service.
PROCEPT BioRobotics Corporation held its annual stockholder meeting on June 9, 2026. Stockholders elected three directors—Antal Desai, Mary Garrett, and Frederic Moll, M.D.—to serve until the 2029 annual meeting, with each receiving over 28 million votes in favor.
Stockholders also ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2026, with 47,328,539 votes for, 21,691 votes withheld, and 23,133 abstentions. In addition, they approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 26,984,867 votes for, 9,924,704 votes withheld, 45,735 abstentions, and 10,418,057 broker non-votes.
PROCEPT BioRobotics Corp executive sells small number of shares for tax withholding. EVP and Chief Legal Officer Nouri Alaleh sold 285 shares of common stock at an average price of $28.48 per share in an open‑market transaction.
According to the footnote, this sale was executed under the company’s sell‑to‑cover process to satisfy tax obligations related to restricted stock units that vested on June 5, 2026. After the transaction, Alaleh directly holds 105,069 shares of PROCEPT BioRobotics common stock, so the sale represents a very small portion of his overall holdings.
PROCEPT BioRobotics EVP and CFO Kevin Waters reported a small sale of 357 shares of common stock. The shares were sold on June 8, 2026 at an average price of $28.479 per share. According to the filing, the sale was made through the company’s sell-to-cover process to satisfy tax withholding obligations tied to Restricted Stock Units that vested on June 5, 2026. After this transaction, Waters directly owns 151,201 shares, indicating the sale was minor relative to his overall holdings.
PROCEPT BioRobotics EVP and CTO Barry L. Templin reported a small sale of 358 shares of Common Stock on June 8, 2026 at $28.479 per share. According to the footnotes, this transaction was executed under the company’s sell-to-cover process to satisfy tax withholding obligations related to Restricted Stock Units that vested on June 5, 2026, indicating it was a routine tax-driven event rather than a discretionary sale. After this transaction, Templin directly holds 68,953 shares of PROCEPT BioRobotics common stock. The footnotes also note that his holdings include 860 shares acquired on May 14, 2026 through the company’s 2021 Employee Stock Purchase Plan.
The issuer notice reports a proposed sale of 285 shares of common stock under a Form 144. The filing lists a Restricted Stock Vesting event dated 06/05/2026 and a filing/processing date of 06/08/2026. The transaction is described as compensation-related and lists an issuer and broker reference.
PRCT submitted a Rule 144 notice regarding the proposed sale of 357 shares of Common Stock that vested on 06/05/2026. The filing lists a trade/filing date of 06/08/2026 and a reported value of $10,167.00 associated with those shares.
The filing also records prior activity by Kevin Waters: a sale of 706 shares on 03/17/2026 with an aggregate figure of $19,876.16. The securities are listed for NASDAQ under CUSIP 56918844.
PRCT reported an insider sale notice for previously restricted common stock. The filing lists 358 shares designated "Securities To Be Sold" tied to Restricted Stock Vesting with an effective date of 06/05/2026. It also records 882 shares sold on 03/17/2026 by Barry L. Templin.
AllianceBernstein L.P. amended its Schedule 13G to report 147,327 shares of PROCEPT BioRobotics Corp Common Stock held in discretionary client accounts. The filing states AllianceBernstein has sole voting power for 146,027 shares and sole dispositive power for 147,327 shares, representing 0.3% of the class. The amendment is signed on 05/15/2026.